Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Malaga – page 84

1 063 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Malaga at a glance
1 063
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 063 trials in Malaga

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Partial seizures

Not recruiting

Study on the Effects of Azetukalner in Reducing Focal-Onset Seizures for Patients with Epilepsy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Cardiac failure

Not recruiting

Study on Stopping Medication in Heart Failure Patients with Cardiac Resynchronization Therapy Using Eplerenone, Valsartan, and Bisoprolol Fumarate

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Prostate cancer metastatic

Not recruiting

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Neoplasm

Not recruiting

Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986408
  • Sponsor:Bristol Myers Squibb International Corporation

Tourette's disorder

Not recruiting

Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette's Disorder

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.

Non-small cell lung cancer

Not recruiting

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Colorectal cancer+5

Not recruiting

Study of Subcutaneous Nivolumab with or without Recombinant Human Hyaluronidase PH20 for Patients with Lung, Kidney, Melanoma, Liver, Colorectal, or Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

  • Lupus skin manifestations
  • Neuromuscular disorders
  • Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

  • Viral infections
  • Vaccine combinations
  • Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

  • Non-muscle invasive treatments
  • Metastatic disease management
  • Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

  • Airway inflammation
  • Pulmonary function
  • Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.